A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.
Also called NCT01059812
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 424 participants
- Sponsor
- Registry
-
NCT01059812
-
- Other papers using this trial's data
- Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial
- Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Hong Kong SAR China, Japan, Malaysia, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01059812. Randomized; no masking; primary purpose treatment. Start 2010-02-01 (actual); primary completion 2010-12-23 (actual). Results posted on 2015-11-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
- Acronym
- BOOST™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- biphasic insulin aspart 30
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01059812- Content hash
b04b42d7450fc7ebd737fcbc2f4377c47d964495bf8c74ac3008933c4b0b15be